AbbVie, J&J to add proprietary data to AI protein model in bid to accelerate drug discovery
Posted:
Life sciences data company Apheris on Thursday announced an effort to boost the capabilities of protein AI models by uniting several pharmaceutical companies’ proprietary data. Apheris’ consortium of pharma companies is partnering with OpenFold3 — Columbia professor Mohammed AlQuraishi’s open-source dupe of AlphaFold3 — to train the model on AbbVie and Johnson & Johnson’s vast stores of structural data. The collaboration will focus on structures relevant to drug discovery, such as small molecule-protein and antibody-antigen interactions.
A new AI framework can detect neurological disorders by analyzing speech with over 90% accuracy. The model, called CTCAIT, captures subtle patterns in voice that may indicate early symptoms of diseases like Parkinson’s, Huntington’s, and Wilson disease.
Read more here.